Table 2.
All | Northern Africa | Middle Africa | Eastern Africa | Western Africa | Southern Africa | |
---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Kantele et al. (Finnish study) [6] | ||||||
total no. of travellers to subregion (% of all) | 196 | 3 (1.5) | 4 (2.0) | 86 (43.9) | 78 (39.8) | 25 (12.8) |
ESBL-PE (+) | 25 (12.8) | 2 (66.7) | 1 (25.0) | 14 (16.3) | 5 (6.4) | 3 (12.0) |
AB | 34 (17.3) | 1 (33.3) | 1 (25.0) | 13 (15.1) | 15 (19.2) | 4 (16.2) |
TD | 71 (36.2) | 1 (33.3) | 1 (25.0) | 34 (39.5) | 29 (37.2) | 6 (24.0) |
Paltansing et al. (Dutch study I) [4] | ||||||
total no. of travellers to subregion (% of all) | 103 | 13 (12.6) | 7 (6.8) | 54 (52.4) | 12 (11.7) | 17 (16.5) |
ESBL-PE (+) | 29 (28.2) | 7 (53.8) | 3 (42.9) | 14 (25.9) | 4 (33.3) | 1 (5.9) |
AB | 8 (7.8) | 2 (15.4) | 1 (14.3) | 3 (5.6) | 2 (16.7) | 0 (0.0) |
TD | 39 (37.9) | 7 (53.8) | 4 (57.1) | 19 (35.2) | 5 (41.7) | 4 (23.5) |
Reuland et al. (Dutch study II) [10] | ||||||
total no. of travellers to subregion (% of all) | 97 | 12 (12.4) | 4 (4.1) | 45 (46.4) | 20 (20.6) | 16 (16.5) |
ESBL-PE (+) | 7 (7.2) | 3 (25.0) | 0 (0.0) | 2 (4.4) | 2 (10.0) | 0 (0.0) |
AB | 2 (2.1) | 0 (0.0) | 0 (0.0) | 2(4.4) | 1 (16.7) | 0 (0.0) |
TD | 43 (44.3) | 5 (41.7) | 2 (50.0) | 17 (37.8) | 14 (70.0) | 5 (31.3) |
Combined total of the three studies | ||||||
total no. of travellers to subregion (% of all) | 396 | 28 (7.1) | 15 (3.8) | 185 (46.7) | 110 (27.8) | 58 (14.6) |
ESBL-PE (+) | 61 (15.4) | 12 (42.9) | 4 (26.7) | 30 (16.2) | 11 (10.0) | 4 (6.9) |
AB | 45 (11.4) | 3 (10.7) | 2 (13.3) | 18 (9.7) | 18 (16.4) | 4 (6.9) |
TD | 153 (38.6) | 13 (46.4) | 7 (46.7) | 70 (37.8) | 48 (43.6) | 15 (25.9) |
AB antibiotic use, TD travellers’ diarrhoea